Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
192.28
+1.33 (0.69%)
Sep 21, 2026, 1:04 PM EDT - Market open
Revolution Medicines Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
883
Market Cap
41.21B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 11.58M | -23.80M | -67.27% |
| Dec 31, 2022 | 35.38M | 5.99M | 20.38% |
| Dec 31, 2021 | 29.39M | -13.59M | -31.62% |
| Dec 31, 2020 | 42.98M | -7.06M | -14.10% |
| Dec 31, 2019 | 50.04M | 29.88M | 148.16% |
| Dec 31, 2018 | 20.17M | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 15.53B |
| BeOne Medicines AG | 6.13B |
| Incyte | 5.82B |
| argenx SE | 5.32B |
| Alnylam Pharmaceuticals | 4.80B |
| Genmab | 4.13B |
| BioNTech SE | 3.03B |
| Royalty Pharma | 2.54B |
RVMD News
- 6 days ago - Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer - GlobeNewsWire
- 16 days ago - Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off. - Business Insider
- 18 days ago - New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines' RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer - GlobeNewsWire
- 24 days ago - Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent - WSJ
- 25 days ago - Revolution Medicines Transcript: FDA announcement - Transcripts
- 25 days ago - Revolution Medicines Slides: FDA announcement - Filings
- 25 days ago - Revolution Medicines Press release: FDA announcement - Filings
- 26 days ago - U.S. FDA Approves Revolution Medicines' RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer - GlobeNewsWire